LFCR
Lifecore Biomedical, Inc. NASDAQ Listed Feb 15, 1996$5.54
+0.36%
vs $5.52
Mkt Cap $192.9M
52w Low $3.66
36.4% of range
52w High $8.82
50d MA $5.09
200d MA $6.60
P/E (TTM)
—
EV/EBITDA
—
P/B
144.3x
Debt/Equity
97.9x
ROE
308.2%
P/FCF
-14.2x
RSI (14)
63.10
ATR (14)
$0.32
Beta
0.88
50d MA
$5.09
200d MA
$6.60
Avg Volume
193.5K
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
3515 Lyman Boulevard · Chaska, MN 55318 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -0.27 | -0.16 | +40.7% | 4.37 | +0.2% | -0.2% | -4.8% | -2.2% | -1.0% | +0.7% | — |
| Nov 6, 2025 | AMC | -0.30 | -0.29 | +3.3% | 6.62 | -0.5% | +3.5% | +6.4% | +6.2% | +6.2% | -4.0% | — |
| Aug 7, 2025 | AMC | -0.09 | -0.10 | -11.1% | 7.76 | -3.4% | -6.7% | -0.3% | +5.7% | +1.4% | -4.1% | — |
| Apr 3, 2025 | AMC | -0.14 | -0.19 | -35.7% | 6.81 | -7.5% | -22.3% | -3.6% | +2.2% | +19.6% | -8.2% | — |
| Jan 2, 2025 | AMC | -0.27 | -0.25 | +7.4% | 6.66 | +6.5% | +14.4% | -9.8% | -14.0% | -1.9% | +8.4% | — |
| Aug 26, 2024 | AMC | -0.12 | -0.15 | -25.0% | 6.34 | -8.7% | -25.2% | -16.2% | -3.8% | +14.7% | -0.2% | — |
| Aug 9, 2024 | AMC | -0.12 | -0.41 | -241.7% | 5.01 | -0.2% | +8.4% | +11.2% | -3.8% | +2.9% | -3.8% | — |
| May 22, 2024 | AMC | -0.23 | 0.43 | +285.7% | 5.83 | +1.2% | -2.4% | -1.2% | -0.7% | +2.5% | +1.0% | — |
| Dec 29, 2023 | AMC | -0.23 | 0.39 | +269.7% | 6.19 | -0.6% | +3.1% | -0.5% | -0.5% | +12.5% | +6.9% | — |
| Aug 31, 2023 | AMC | -0.07 | -0.89 | -1171.4% | 8.00 | +0.0% | -1.6% | -0.5% | +0.0% | -1.0% | -3.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Barrington Research | Maintains | Outperform → Outperform | — | $5.12 | $5.13 | +0.2% | -3.5% | +2.6% | +3.7% | -2.5% | +0.6% |
| Mar 27 | Barrington Research | Maintains | Outperform → Outperform | — | $3.87 | $3.84 | -0.8% | -5.4% | +3.6% | -1.8% | +3.2% | +0.0% |
| Mar 24 | Barrington Research | Maintains | Outperform → Outperform | — | $4.05 | $4.00 | -1.2% | -1.2% | +4.8% | -7.6% | -5.4% | +3.6% |
| Mar 17 | Barrington Research | Upgrade | Market Perform → Outperform | — | $4.37 | $4.38 | +0.2% | -0.2% | -4.8% | -2.2% | -1.0% | +0.7% |
| Jan 3 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $6.66 | $7.09 | +6.5% | +14.4% | -9.8% | -14.0% | -1.9% | +8.4% |
| Nov 22 | Craig-Hallum | Maintains | Buy → Buy | — | $6.98 | $7.14 | +2.3% | +4.7% | +2.1% | -0.3% | +0.8% | -1.2% |
| Aug 28 | Barrington Research | Downgrade | Outperform → Market Perform | — | $4.74 | $4.60 | -3.0% | -16.2% | -3.8% | +14.7% | -0.2% | -3.4% |
| Sep 1 | Barrington Research | Maintains | Outperform → Outperform | — | $8.00 | $8.00 | +0.0% | -1.6% | -0.5% | +0.0% | -1.0% | -3.4% |
| Sep 1 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $8.00 | $8.00 | +0.0% | -1.6% | -0.5% | +0.0% | -1.0% | -3.4% |
| Jun 2 | Barrington Research | Maintains | Outperform → Outperform | — | $8.25 | $8.66 | +5.0% | -1.2% | +2.6% | +1.7% | -1.9% | +0.4% |
| May 24 | Barrington Research | Maintains | Outperform → Outperform | — | $8.05 | $7.83 | -2.7% | +3.9% | -0.1% | -4.9% | +0.9% | +2.2% |
| Mar 21 | Barrington Research | Maintains | Outperform → Outperform | — | $3.10 | $2.97 | -4.2% | +4.8% | +0.2% | -6.6% | +2.6% | +2.9% |
| Mar 20 | Barrington Research | Maintains | Outperform → Outperform | — | $1.67 | $1.81 | +8.4% | +85.6% | +4.8% | +0.2% | -6.6% | +2.6% |
| Mar 20 | Stephens & Co. | Downgrade | Overweight → Equal Weight | — | $1.67 | $1.81 | +8.4% | +85.6% | +4.8% | +0.2% | -6.6% | +2.6% |
| Mar 17 | Stephens & Co. | Maintains | Overweight → Overweight | — | $5.11 | $3.30 | -35.4% | -67.3% | +85.6% | +4.8% | +0.2% | -6.6% |
| Oct 6 | Barrington Research | Maintains | Outperform → Outperform | — | $8.70 | $8.69 | -0.1% | +0.1% | -5.4% | -2.3% | +2.2% | -2.1% |
| Aug 10 | Barrington Research | Upgrade | Market Perform → Outperform | — | $10.80 | $10.96 | +1.5% | +2.0% | +2.6% | -0.7% | +3.0% | -0.1% |
| Jul 20 | Stephens & Co. | Maintains | Overweight → Overweight | — | $10.07 | $10.50 | +4.3% | +6.7% | -2.3% | -1.9% | +0.5% | -0.4% |
| Apr 6 | Barrington Research | Downgrade | Outperform → Perform | — | $11.33 | $10.21 | -9.9% | -6.0% | +0.8% | -2.1% | +0.3% | -1.1% |
| Apr 5 | Barrington Research | Downgrade | Outperform → Market Perform | — | $11.61 | $11.69 | +0.7% | -2.4% | -6.0% | +0.8% | -2.1% | +0.3% |
| Oct 3 | Roth Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jul 29 | Roth Capital | Maintains | Buy → Buy | — | $12.44 | $12.40 | -0.3% | -9.1% | -3.3% | -2.7% | +1.5% | -2.6% |
| Jun 1 | Barrington Research | Upgrade | Market Perform → Outperform | — | $11.97 | $11.98 | +0.1% | -2.8% | +6.9% | -1.0% | +3.6% | +0.2% |
| Apr 8 | Roth Capital | Maintains | Buy → Buy | — | $10.95 | $9.38 | -14.3% | -8.5% | -1.1% | +1.5% | +3.4% | +1.4% |
| Jan 5 | Barrington Research | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Apr 7 | Roth Capital | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Apr 1 | Imperial Capital | Maintains | Outperform → Outperform | — | $13.95 | $13.70 | -1.8% | +2.4% | +1.5% | +2.0% | -0.9% | -1.2% |
| Oct 8 | Feltl & Co. | Downgrade | Buy → Hold | — | $11.32 | $11.30 | -0.2% | +1.9% | -3.5% | +0.1% | +2.2% | +0.4% |
| Apr 13 | Northland Capital Markets | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K · 2.02
!! High
Lifecore Biomedical, Inc. -- 8-K 2.02: Earnings Results
Lifecore Biomedical reported earnings results in an 8-K filing, with detailed financial performance data available in the attached press release exhibit for investor review.
May 6
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Lifecore Biomedical disclosed material information via press release on March 16, 2026, potentially signaling significant news about operations, partnerships, or financials that could materially impact LFCR's stock valuation and investor positioning.
Mar 16
8-K
Lifecore Biomedical, Inc. -- 8-K Filing
Lifecore Biomedical has announced a shareholder proposal deadline of March 16, 2026, requiring submissions to comply with SEC regulations and company bylaws.
Mar 5
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 12
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Ultra-Small Company Market Fund | 56,900 | $212K | Mar 2026 |
| 2 | Small Cap Index Fund | 10,016 | $37K | Mar 2026 |
| 3 | Gabelli Dividend & Income Trust | 10,000 | $37K | Mar 2026 |
| 4 | Avantis Total Equity Markets ETF | 2,312 | $17K | Feb 2026 |
| 5 | Gabelli Global Mini Mites Fund | 3,500 | $13K | Mar 2026 |
| 6 | Small Cap Core Fund | 2,841 | $11K | Mar 2026 |
| 7 | Motley Fool Next Index ETF | 602 | $4K | Feb 2026 |
| 8 | Penn Series Small Cap Index Fund | 900 | $3K | Mar 2026 |
| 9 | Motley Fool Innovative Growth Factor ETF | 56 | $403 | Feb 2026 |
| 10 | Russell 2000 Fund | 65 | $242 | Mar 2026 |
| 11 | Russell 2000 1.5x Strategy Fund | 39 | $145 | Mar 2026 |
| 12 | Avantis U.S. Small Cap Equity ETF | 5 | $36 | Feb 2026 |
Valuation
Market Cap
$192.9M
Enterprise Value
$311.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.01x
P/B
144.27x
P/S
1.43x
P/FCF
-14.16x
EV/EBITDA
—
Shares Out
34.8M
Financials (TTM)
Revenue
$135.2M
Net Income
-$34.1M
EBITDA
-$1.0M
Free Cash Flow
-$13.6M
Op Cash Flow
-$206K
EPS Basic
$-1.27
EPS Diluted
$-1.03
EPS Forward
$-0.48
Gross Margin
31.2%
Op Margin
-0.1%
Net Margin
-25.2%
Balance Sheet
Total Assets
$239.3M
Total Liab.
$238.0M
Total Equity
$1.3M
Cash
$8.3M
LT Debt
$127.0M
Book Value/Sh
$0.04
Debt/Equity
97.92x
Current Ratio
2.84
Quick Ratio
1.77
Returns & Growth
ROE
308.2%
ROA
-13.8%
ROIC
-8.1%
Rev Growth YoY
+0.5%
EPS Growth YoY
-425.6%
Price Returns
2W
+10.3%
1M
-1.0%
3M
-30.3%
6M
-36.5%
12M
-25.8%
Technicals
52W High
$8.82
52W Low
$3.66
50d MA
$5.09
200d MA
$6.60
RSI (14)
63.10
ATR (14)
$0.32
Beta
0.88
Avg Volume
194K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 25, 2026 6:55pm
· Source: financialmodelingprep.com